Delving into the Latest Updates on PRT-2761 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

PRT, PRT 2761, PRT2761

Target

Syk

Action

inhibitors

Mechanism

Syk inhibitors(Spleen tyrosine kinase inhibitors)

Therapeutic Areas

Immune System DiseasesEye Diseases

Active Indication

Conjunctivitis, Allergic

Inactive Indication-

Originator Organization

Portola Pharmaceuticals LLC

Active Organization

Portola Pharmaceuticals LLC

Inactive Organization

Beijing Orange Xin Data Technology Co., Ltd

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H20O6

InChIKeyGSPFUBNBRPVALJ-VIEAGMIOSA-N

CAS Registry56299-00-4

Babies born extremely preterm (<28 weeks of pregnancy) require support to breathe. Some babies require help to breathe from a breathing machine (mechanical ventilator). While this keeps babies alive, it may damage their lungs. To reduce this damage, doctors and nurses take particular care to try and provide the gentlest breathing support possible. However, evidence is still required to determine how to best support babies' breathing, whilst preventing lung damage and longer-term lung problems.
This clinical trial aims to compare two ways of adjusting a common setting on the breathing machine. This setting is called the pressure rise time or PRT. The PRT determines how quickly the breathing machine inflates a premature baby's lungs. A short PRT quickly inflates the lungs. A long PRT inflates the lungs more slowly. Previous research suggests that more slowly inflating the baby's lungs may cause less lung damage and still allow oxygen to be delivered to and carbon dioxide to be cleared from the lungs. However, larger studies are required to determine whether this should become the standard treatment.
This study investigates whether inflating the baby's lungs more slowly (long PRT) using the breathing machine is as effective as the PRT setting currently used (short PRT, more quickly inflating the lungs).
The main question it aims to answer is: Does how quickly the breathing machine inflates an extremely preterm baby's lung impact their oxygen levels?

Start Date01 Feb 2026

Sponsor / Collaborator

Murdoch Childrens Research Institute

[+2]

NCT03320434

/ CompletedPhase 2

A Single-Center, Randomized, Double-Masked, Vehicle and Active-Controlled, Dose-Ranging Phase 2 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model (Ora-CAC®)

To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.

Start Date13 Oct 2017

Sponsor / Collaborator

Beijing Orange Xin Data Technology Co., Ltd

100 Clinical Results associated with PRT-2761

Login to view more data

100 Translational Medicine associated with PRT-2761

Login to view more data

100 Patents (Medical) associated with PRT-2761

Login to view more data

106

Literatures (Medical) associated with PRT-2761

18 Apr 2025·ACS Chemical Biology

Activation of the Trichodimerol Pathway through Deletion of mcrA in Marine Penicillium rubens YAP001

Article

Author: Lee, Ching-Kuo ; Aguirre, Emily ; Herrero-MacKenzie, Hugo Edward ; Shyong, Jennifer ; Tran Huynh, Quoc-Dung ; Rabot, Chris ; Wang, Clay C. C. ; Yuan, Bo ; Dziedzic, Stella ; Kenkel, Carly D. ; Stajich, Jason E.

Fungal secondary metabolites (SMs) are complex organic compounds comprising a variety of biological activities that are essential in medicine. These natural products can be found in various environments, with studies demonstrating the importance of studying marine-sourced fungi due to the increased potency of the compounds they produce. In this study, we sourced a Penicillium rubens YAP001 strain isolated from Exaiptasia diaphana and explored an avenue for the upregulation of its SMs by combining the one-strain-many-compounds (OSMAC) strategy with genetic manipulation of negative global regulator of secondary metabolism, mcrA. Here, we generated a mcrAΔ strain of marine P. rubens (YAP001), which led to the detection of sorbicillinoids, which is significant due to the prior discovery that these compounds illicit cytotoxic effects that have the potential as an anticancer agent. Specifically, we found that sorbicillin was not only upregulated but the mutant strain also produced the dimeric product, trichodimerol, which often exhibits stronger biological activities compared to sorbicillin. Furthermore, the reduced form of trichodimerol, dihydrotrichodimerol, was also detected in the mutant strain. This work suggests that genetic manipulation of global regulators in combination with the OSMAC method in filamentous fungi is a promising technique for upregulating pathways of interest for small-molecule drug discovery.

01 Feb 2025·PLANTA

Exploring the plant-growth promoting bacterium Herbaspirillum seropedicae as catalyst of microbiome remodeling and metabolic changes in wheat plants

Article

Author: Cordeiro, Carlos ; Tenreiro, Rogério ; Silva, Marta Sousa ; Carril, Pablo ; Cruz, Cristina ; Ngendahimana, Ephrem

MAIN CONCLUSION:

Inoculation with the PGPB Herbaspirillum seropedicae shapes both the structure and putative functions of the wheat microbiome and causes changes in the levels of various plant metabolites described to be involved in plant growth and health. Plant growth promoting bacteria (PGPB) can establish metabolic imprints in their hosts, contributing to the improvement of plant health in different ways. However, while PGPB imprints on plant metabolism have been extensively characterized, much less is known regarding those affecting plant indigenous microbiomes, and hence it remains unknown whether both processes occur simultaneously. In this study, both 16S amplicon and ITS sequencing analyses were carried out to study both the structural as well as the putative functional changes in the seed-borne endophytic microbiome of wheat plants inoculated with the PGPB Herbaspirillum seropedicae strain RAM10. Concomitantly, Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS) analyses were used to investigate the alterations in the root metabolome of PGPB-inoculated plants. PGPB inoculation led to marked differences in the composition of the root microbiome, accompanied by the differential enrichment of microorganisms with putative roles in both plant energy and nitrogen metabolism. In addition, metabolome analyses showed that the levels of 16 metabolites belonging to the phenylpropanoid, terpenoid, and unsaturated fatty acid families were significantly altered in PGPB-inoculated plants. These findings shed light on the interplay between PGPB, the plant and its associated microbiome, indicating that PGPB can act as the driving force mediating long-lasting changes in both the plant metabolome and the plant microbiome.

01 Jan 2025·INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY

An atoxigenic Aspergillus flavus PA67 from Shandong province exhibits potential in biocontrol against toxigenic Aspergillus flavus, Sclerotium rolfsii, and Fusarium proliferatum

Article

Author: Zhang, Yanyan ; Ren, Junhe ; Xu, Jia ; Kong, Qing

Peanuts and corn are susceptible to various soil-borne fungi, leading to significant economic losses. Atoxigenic Aspergillus flavus have been widely used as biocontrol agents for managing aflatoxin contamination because of their minimal environmental impact, strong competitive ability, and sustained inhibition effect. After multiple identifications and cluster amplification pattern (CAP) analysis, three atoxigenic A. flavus PA04, PA10 and PA67 were isolated from peanut samples in Shandong Province, which can reduce aflatoxin levels by up to 90 %. Our study revealed that atoxigenic A. flavus also competed vigorously with Sclerotium rolfsii and Fusarium proliferatum for nutrition and space, achieving notable inhibition rates of up to 90.4 % and 90.6 %, respectively. The supernatants of atoxigenic A. flavus also inhibited the growth of S. rolfsii and F. proliferatum, with PA67 demonstrating the most significant effect. Whole genome sequencing revealed that PA67 contains multiple glycoside hydrolases and metabolites with antifungal activity. The kojic acid production of PA67 was higher than that of PA04 and PA10, reaching 17.48 g/L, which has a significant inhibition on sclerotia germination. PA67 supernatant significantly inhibited the hyphae growth of S. rolfsii and F. proliferatum, and down-regulated genes related to sclerotia and fumonisin formation. This study demonstrates the biocontrol potential of PA67 against three soil-borne fungi and is the first investigation of atoxigenic A. flavus to inhibit S. rolfsii and F. proliferatum.

2

News (Medical) associated with PRT-2761

13 Apr 2021

·www.globenewswire.com

Global Allergic Conjunctivitis Market (2020 to 2027) - Featuring Santen Pharmaceutical, Alcon, Portola Pharmaceuticals and Ocular Therapeutix Among Others

Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis" report has been added to ResearchAndMarkets.com's offering. Allergic conjunctivitis is common ophthalmic disorder caused by reactions to allergens like pollen or mold spores, dust mites and animal fur. The eyeball has a membrane called conjunctiva which is receptive towards the irritation from allergens.In July 2020, IACTA Pharmaceuticals & Zhaoke Ophthalmology Pharmaceuticals Ltd has signed an agreement to accelerate the development of drugs called IC265 and IC 270. Earlier they were develop to treat dry eye and later for allergic conjunctivitis.There are many types of allergic conjunctivitis such as seasonal allergic conjunctivitis is caused by airborne mold spores, spring, late summer, or early fall and disappear during the winter month & perennial allergic conjunctivitis is caused by dust, mites, animal dander, and other non-seasonal allergens.According to this research, Allergic Conjunctivitis Market was US$ 1.5 Billion in 2020 is expected to grow with a CAGR of 8.81% and reach US$ 2.7 Billion by 2027.There has been significant increase allergic conjunctivitis due to increase in the use of chemicals and pollution caused by urbanization, industrialization and climate change. The increase in awareness of allergic conjunctivitis is associated its medical treatment & upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc. is one of the factors driving the market.Many Pharmaceutical companies are trying to develop many new possibilities of treatment for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC's EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials.The publisher has studied by region of North America followed by Europe and Asia-Pacific. The allergic conjunctivitis treatment market in Asia Pacific is expected to grow rapidly, due to having a large population base and increased demand of improved health facilities.Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Allergic Conjunctivitis Market and Patients Analysis5.1 Market5.2 Patient Numbers5.3 Treated Patient Numbers6. Share Analysis - Global Allergic Conjunctivitis6.1 Country Market Share6.2 Patients Population Share6.3 Treated Patients Population Share6.4 By Disease Type Share7. India - Allergic Conjunctivitis Analysis7.1 Patient Numbers7.2 Treated Patient Numbers7.3 Market8. China - Allergic Conjunctivitis Analysis8.1 Patient Numbers8.2 Treated Patient Numbers8.3 Market9. Japan - Allergic Conjunctivitis Analysis9.1 Patient Numbers9.2 Treated Patient Numbers9.3 Market10. United States - Allergic Conjunctivitis Analysis10.1 Patient Numbers10.2 Treated Patient Numbers10.3 Market11. United Kingdom - Allergic Conjunctivitis Analysis11.1 Patient Number11.2 Treated Patient Numbers11.3 Market12. France - Allergic Conjunctivitis Analysis12.1 Patient Numbers12.2 Treated Patient Numbers12.3 Market13. Germany - Allergic Conjunctivitis Analysis13.1 Patient Numbers13.2 Treated Patient Numbers13.3 Market14. Italy - Allergic Conjunctivitis Analysis14.1 Patient Numbers14.2 Treated Patient Numbers14.3 Market15. Spain - Allergic Conjunctivitis Analysis15.1 Patient Numbers15.2 Treated Patient Numbers15.3 Market16. Disease Type - Global Allergic Conjunctivitis Market16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)16.2 Vernal Keratoconjunctivitis (VKC)16.3 Atopic Keratoconjunctivitis (AKC)16.4 Giant Papillary Conjunctivitis (GPC)17. Global Allergic Conjunctivitis Pipeline Drugs17.1 Zerviate17.2 OTX-DP (Dexamethasone Insert)17.3 ADX-10217.4 PRT276117.5 CVXL-007417.6 AK-00217.7 Bertilimumab17.8 Reproxalap17.9 ST-26617.10 SYL-11601118. Company Analysis18.1 Santen Pharmaceutical18.1.1 Company Overview18.1.2 Recent Developments18.1.3 Financial Insight18.2 Alcon Inc. (Novartis)18.2.1 Company Overview18.2.2 Recent Developments18.2.3 Financial Insight18.3 Portola Pharmaceuticals Inc.18.3.1 Company Overview18.3.2 Recent Developments18.3.3 Financial Insight18.4 Ocular Therapeutix Inc.18.4.1 Company Overview18.4.2 Recent Developments18.4.3 Financial InsightFor more information about this report visit

12 Apr 2021

·www.globenewswire.com

Global Allergic Conjunctivitis Market (2020 to 2027) -

Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Allergic Conjunctivitis Market, Global Forecast Treated Patients By Countries, Disease Type, Pipeline Drugs, Company Analysis" report has been added to ResearchAndMarkets.com's offering. Allergic conjunctivitis is common ophthalmic disorder caused by reactions to allergens like pollen or mold spores, dust mites and animal fur. The eyeball has a membrane called conjunctiva which is receptive towards the irritation from allergens.In July 2020, IACTA Pharmaceuticals & Zhaoke Ophthalmology Pharmaceuticals Ltd has signed an agreement to accelerate the development of drugs called IC265 and IC 270. Earlier they were develop to treat dry eye and later for allergic conjunctivitis.There are many types of allergic conjunctivitis such as seasonal allergic conjunctivitis is caused by airborne mold spores, spring, late summer, or early fall and disappear during the winter month & perennial allergic conjunctivitis is caused by dust, mites, animal dander, and other non-seasonal allergens.According to this research, Allergic Conjunctivitis Market was US$ 1.5 Billion in 2020 is expected to grow with a CAGR of 8.81% and reach US$ 2.7 Billion by 2027.There has been significant increase allergic conjunctivitis due to increase in the use of chemicals and pollution caused by urbanization, industrialization and climate change. The increase in awareness of allergic conjunctivitis is associated its medical treatment & upcoming therapies such as Zerviate, ADX-102, PRT-2761, OTX-DP etc. is one of the factors driving the market.Many Pharmaceutical companies are trying to develop many new possibilities of treatment for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC's EM-100 is currently in phase 3 of clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two third of new treatment options are in phase 2 or 3 of clinical trials.The publisher has studied by region of North America followed by Europe and Asia-Pacific. The allergic conjunctivitis treatment market in Asia Pacific is expected to grow rapidly, due to having a large population base and increased demand of improved health facilities.Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Allergic Conjunctivitis Market and Patients Analysis5.1 Market5.2 Patient Numbers5.3 Treated Patient Numbers6. Share Analysis - Global Allergic Conjunctivitis6.1 Country Market Share6.2 Patients Population Share6.3 Treated Patients Population Share6.4 By Disease Type Share7. India - Allergic Conjunctivitis Analysis7.1 Patient Numbers7.2 Treated Patient Numbers7.3 Market8. China - Allergic Conjunctivitis Analysis8.1 Patient Numbers8.2 Treated Patient Numbers8.3 Market9. Japan - Allergic Conjunctivitis Analysis9.1 Patient Numbers9.2 Treated Patient Numbers9.3 Market10. United States - Allergic Conjunctivitis Analysis10.1 Patient Numbers10.2 Treated Patient Numbers10.3 Market11. United Kingdom - Allergic Conjunctivitis Analysis11.1 Patient Number11.2 Treated Patient Numbers11.3 Market12. France - Allergic Conjunctivitis Analysis12.1 Patient Numbers12.2 Treated Patient Numbers12.3 Market13. Germany - Allergic Conjunctivitis Analysis13.1 Patient Numbers13.2 Treated Patient Numbers13.3 Market14. Italy - Allergic Conjunctivitis Analysis14.1 Patient Numbers14.2 Treated Patient Numbers14.3 Market15. Spain - Allergic Conjunctivitis Analysis15.1 Patient Numbers15.2 Treated Patient Numbers15.3 Market16. Disease Type - Global Allergic Conjunctivitis Market16.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)16.2 Vernal Keratoconjunctivitis (VKC)16.3 Atopic Keratoconjunctivitis (AKC)16.4 Giant Papillary Conjunctivitis (GPC)17. Global Allergic Conjunctivitis Pipeline Drugs17.1 Zerviate17.2 OTX-DP (Dexamethasone Insert)17.3 ADX-10217.4 PRT276117.5 CVXL-007417.6 AK-00217.7 Bertilimumab17.8 Reproxalap17.9 ST-26617.10 SYL-11601118. Company Analysis18.1 Santen Pharmaceutical18.1.1 Company Overview18.1.2 Recent Developments18.1.3 Financial Insight18.2 Alcon Inc. (Novartis)18.2.1 Company Overview18.2.2 Recent Developments18.2.3 Financial Insight18.3 Portola Pharmaceuticals Inc.18.3.1 Company Overview18.3.2 Recent Developments18.3.3 Financial Insight18.4 Ocular Therapeutix Inc.18.4.1 Company Overview18.4.2 Recent Developments18.4.3 Financial InsightFor more information about this report visit

100 Deals associated with PRT-2761

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis, Allergic	Phase 2	United States	Beijing Orange Xin Data Technology Co., Ltd	13 Oct 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03320434 (CTgov)	Phase 2	Conjunctivitis, Allergic	120	PRT-2761 0.5% (PRT-2761 0.5%)	fxvhpsycet(bktgdmrfks) = lvjmadtuzy slfhjwadvw (pcntloizkj, 0.9246) View more	-	17 Oct 2022
				PRT-2761 1% (PRT-2761 1%)	fxvhpsycet(bktgdmrfks) = zjqsxnyqwk slfhjwadvw (pcntloizkj, 0.7792) View more